Get notified when PFSA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (worsened) — Material weaknesses remain unremediated one year later, now explicitly carried forward from the 2025 10-K with less specific disclosure about what controls failed.
Profusa faces going-concern doubt, Nasdaq delisting risk, and $30M acquisition amid cash burn
Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q Jun 13, 2025 · ~1 min read
Key Changes
-
high
Management disclosed substantial doubt about ability to continue as a going concern, driven by recurring losses, negative cash flow, and $12.5M debt due within 12 months. Q1 2026 operating cash burn reached $2.6M, up from $0.5M in Q1 2025.
MD&A: Going Concern & Liquidity verify on EDGAR → -
high
Company must meet Nasdaq minimum bid price and stockholders' equity requirements by July 6, 2026 or face delisting. Already transferred from Global Market to Capital Market after failing multiple listing standards.
MD&A: Nasdaq Compliance verify on EDGAR → -
high
Agreed to acquire Bio Insights' PanOmics multi-omics platform for $30M in convertible preferred stock, subject to shareholder approval. Represents strategic expansion beyond core biosensing products but introduces significant dilution risk.
MD&A: Asset Acquisition verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.
Partner
Trade PFSA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · May 28, 2026 9:06 PM